Abstract
Unlike other sarcomas, high-grade osteosarcoma (HGOS) is characterized by complex, unbalanced karyotypes and alterations in multiple genes and pathways. Due to HGOS high genetic instability, recurrent chromothripsis (a massive genomic rearrangement due to a cataclysmic event in which chromosomes are fragmented and subsequently aberrantly assembled), kataegis (high number of genetic changes due to localized hypermutation areas), and chromoplexy (a process generating chimeric chromosomes) are rather common events and lead to multiple malignant cell populations within the same tumor [1, 2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 2014;7(1):104–12. https://doi.org/10.1016/j.celrep.2014.03.003. S2211-1247(14)00165-X [pii].
Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet. 2003;145(1):1–30. S0165460803001055 [pii].
Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma—connecting aetiology, biology and therapy. Nat Rev Endocrinol. 2017;13(8):480–91. https://doi.org/10.1038/nrendo.2017.16. nrendo.2017.16 [pii].
Hattinger CM, Reverter-Branchat G, Remondini D, Castellani GC, Benini S, Pasello M, et al. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. Eur J Cell Biol. 2003;82(9):483–93. https://doi.org/10.1078/0171-9335-00336. S0171-9335(04)70319-2 [pii].
Hattinger CM, Stoico G, Michelacci F, Pasello M, Scionti I, Remondini D, et al. Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosomes Cancer. 2009;48(4):289–309. https://doi.org/10.1002/gcc.20640.
Hattinger CM, Fanelli M, Tavanti E, Vella S, Ferrari S, Picci P, et al. Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs. 2015;20(3):495–514. https://doi.org/10.1517/14728214.2015.1051965.
Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med. 1995;333(21):1380–5. https://doi.org/10.1056/NEJM199511233332103.
Chan HS, Grogan TM, Haddad G, DeBoer G, Ling V. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst. 1997;89(22):1706–15.
Pakos EE, Ioannidis JP. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer. 2003;98(3):581–9. https://doi.org/10.1002/cncr.11546.
Serra M, Pasello M, Manara MC, Scotlandi K, Ferrari S, Bertoni F, et al. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int J Oncol. 2006;29(6):1459–68.
Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol. 2003;21(3):536–42. https://doi.org/10.1200/JCO.2003.03.144.
Fanelli M, Hattinger CM, Vella S, Tavanti E, Michelacci F, Gudeman B, et al. Targeting ABCB1 and ABCC1 with their specific inhibitor CBT-1(R) can overcome drug resistance in osteosarcoma. Curr Cancer Drug Targets. 2016;16(3):261–74. CCDT-EPUB-71612 [pii].
Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer. 2009;115(22):5339–48. https://doi.org/10.1002/cncr.24566.
Meyers PA. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther. 2009;9(8):1035–49. https://doi.org/10.1586/era.09.69.
Meyers PA, Chou AJ. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. Adv Exp Med Biol. 2014;804:307–21. https://doi.org/10.1007/978-3-319-04843-7_17.
Hattinger CM, Vella S, Tavanti E, Fanelli M, Picci P, Serra M. Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients. Pharmacogenomics. 2016;17(18):2097–114. https://doi.org/10.2217/pgs-2016-0116.
Serra M, Hattinger CM. The pharmacogenomics of osteosarcoma. Pharmacogenomics J. 2017;17(1):11–20. https://doi.org/10.1038/tpj.2016.45. tpj201645 [pii].
Kovac M, Blattmann C, Ribi S, Smida J, Mueller NS, Engert F, et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat Commun. 2015;6:8940. https://doi.org/10.1038/ncomms9940. ncomms9940 [pii].
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Serra, M., Hattinger, C.M. (2020). Biology of Osteosarcomas. In: Picci, P., et al. Diagnosis of Musculoskeletal Tumors and Tumor-like Conditions. Springer, Cham. https://doi.org/10.1007/978-3-030-29676-6_37
Download citation
DOI: https://doi.org/10.1007/978-3-030-29676-6_37
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-29675-9
Online ISBN: 978-3-030-29676-6
eBook Packages: MedicineMedicine (R0)